December 20th, 2021 – Kyoto, Japan – HACARUS INC, the leading provider of big insights from small data, today announced it has been selected by Pfizer Japan for collaboration.
HACARUS participated in an internal accelerator program organized by Pfizer, aiming to contribute to better care for patients, and proposed an advanced collaborative plan using its proprietary AI technology.
The program, run by marketing departments from the six divisions of Pfizer (Internal Medicine, Inflammation & Immunology, Oncology, Rare Diseases, Hospitals, and Vaccines) discussed the contributions to patients that should be made in the future and identified issues. HACARUS was selected as one of the companies with the potential to solve these issues, and a proposal was made for the approach to be taken.
At the final debriefing of the program held in November 2021, four startups including HACARUS took to the stage and proposed to Pfizer’s leadership team advanced collaboration plans. Bases on the outcome on this the two firms are now explore next steps.
About HACARUS INC.
HACARUS INC. provides big insights from small data and has since its founding in 2014 supplied solutions in 100+ AI projects across the Medical and Manufacturing fields. Headquartered in Kyoto, Japan, and backed by Osaka Gas and Miyako Capital (Kyoto University) among others, its technology enables humans to make better, faster, and more reliable decisions, based on data-driven insights. HACARUS’ proprietary AI engine is built using Sparse Modeling, a method that understands data like a human would – by its unique key features and is far more resource, time, and energy-efficient when compared to Deep Learning. To learn more, visit https://hacarus.com